Oncolytic Vaccinia virus and radiotherapy in head and neck cancer

Oral Oncology

Volumn 49, Issue 2, 2013, Pages 108-118

  Mansfield, D ^a   Pencavel, T ^a   Kyula, J N ^a   Zaidi, S ^a   Roulstone, V ^a   Thway, K ^b   Karapanagiotou, L ^a   Khan, A A ^a   McLaughlin, M ^a   Touchefeu, Y ^a   Seth, R ^a   Melcher, A A ^c   Vile, R G ^d   Pandha, H S ^e   Harrington, K J ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Royal Marsden   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

GLV 1h68; Head and neck cancer; Oncolytic; Radiation; Vaccinia virus

Indexed keywords

CASPASE 3; CASPASE 7; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER REGRESSION; CELL KILLING; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; G1 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK CANCER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TIME; TUMOR XENOGRAFT; VACCINIA VIRUS; VIRAL CLEARANCE;

CASPASE 3; CASPASE 7; CELL CYCLE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ENZYME ACTIVATION; HEAD AND NECK NEOPLASMS; HUMANS; ONCOLYTIC VIROTHERAPY; VACCINIA VIRUS;

EID: 84872305052     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.07.019     Document Type: Article

References (18)

1. G.A. Poland, J.D. Grabenstein, and J.M. Neff The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program Vaccine 23 17-18 2005 2078 2081
2. C.T. Hiley, M. Yuan, N.R. Lemoine, and Y. Wang Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours Gene Ther 17 2 2010 281 287
3. G.L. Smith, and B. Moss Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA Gene 25 1 1983 21 28
4. G.L. Smith, A. Vanderplasschen, and M. Law The formation and function of extracellular enveloped vaccinia virus J Gen Virol 83 12 2002 2915 2931
5. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 2005 74 108
6. K.J. Harrington, R. Kazi, S.A. Bhide, K. Newbold, and C.M. Nutting Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents Indian J Cancer 47 3 2010 248 259
7. K.J. Harrington, L.J. Billingham, and T.B. Brunner Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers Br J Cancer 105 5 2011 628 639
8. H. Pandha, A. Melcher, K. Harrington, and R. Vile Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009 Mol Ther 17 6 2009 934 935
9. Y. Touchefeu, G. Vassaux, and K.J. Harrington Oncolytic viruses in radiation oncology Radiotherapy Oncol 99 3 2011 262 270
10. C.I. Bliss The calculation of microbial assays Bacteriol Rev 20 4 1956 243 258
11. W.R. Greco, G. Bravo, and J.C. Parsons The search for synergy: a critical review from a response surface perspective Pharmacol Rev 47 2 1995 331 385
12. A. Biondo, J.V. Pedersen, and E.M. Karapanagiotou Phase I clinical trial of a genetically modified oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging Eur J Cancer 47 2011 S162
13. B.H. Park, T.H. Hwang, and S.G. Kim A phase I-II clinical trial with JX-594, a targeted and GM-CSF-armed oncolytic poxvirus, by intratumoral injection in patients with liver tumors Mol Cancer Ther 6 12 2007 3386s 3387s
14. J. Heo, T. Reid, and L. Ruo A randomized, controlled phase 2 clinical trial of JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with advanced hepatocellular carcinoma: final data Hepatology 54 2011 1426a
15. J. Burke, J. Stephenson, and A. Pelusio Intravenous phase I clinical proof-of-concept trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with refractory metastatic cancers Mol Ther 17 2009 S218
16. F.R. Khuri, J. Nemunaitis, and I. Ganly A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat Med 6 8 2000 879 885
17. K.J. Harrington, M. Hingorani, and M.A. Tanay Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck Clin Cancer Res 16 15 2010 4005 4015
18. E.M. Karapanagiotou, V. Roulstone, and K. Twigger Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies Clin Cancer Res 18 7 2012 2080 2089